Changqing Xie, M.D., Ph.D.
I am interested in exploring the potential mechanism of resistance to treatment with immune checkpoint inhibitor in gastrointestinal (GI) malignancy. My focus is to dissect the role of cancer stem cells in cholangiocarcinoma in terms of developing this therapy resistance.
1) gastrointestinal (GI) malignancy, 2) cancer stem cells, 3) cholangiocarcinoma,
4) immune checkpoint inhibitor
My overall goal is to explore the role of cancer stem cells in the development of treatment resistance to immunotherapy in cholangiocarcinoma with the following steps: 1) To investigate the path of cancer stem cells during cholangiocarcinoma; 2) To study the interaction between cancer stem cells and neighboring immune cells during cholangiocarcinoma pathogenesis; and 3) To identify the potential target agents to control cancer stem cells in cholangiocarcinoma.
Selected Recent Publications
Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer.Hepatology. 69(5): 2048-2060, 2019. [ Journal Article ]
The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.Cancer Immunol Immunother. 68(4): 599-608, 2019. [ Journal Article ]
- J Endocr Soc. 3(1): 284-290, 2018. [ Journal Article ]
I received my M.D. and Ph.D from the Xiangya School of Medicine of Central South University. I completed my postdoctoral training at Morehouse School Medicine and at the University of Michigan before being promoted as junior faculty at the University of Michigan. Before I started internal medicine residency training at East Carolina University, I worked as an Assistant Research Professor at the University of Virginia. I completed hematology oncology training through the NHLBI/NCI Hematology Oncology Fellowship program and joined the Thoracic and Gastrointestinal (GI) Malignancies Branch as an Assistant Clinical Investigator in 2019.
|Claude Fu||Postdoctoral Fellow|
|Nicole A. McGrath||Postbaccalaureate Fellow (CRTA)|